Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ectopic ACTH Syndrome Clear all
Completed No phase listed Observational Accepts healthy volunteers

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

NCT00001180
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
Interventions
Ovine Corticotropin-Releasing Hormone (oCRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1982 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT03817840
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Treatment of Cushing's
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting No phase listed Observational

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT03364803
View directory record Official record
Conditions
Cushing's Disease, Cushing Syndrome, Cushing Disease
Interventions
Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Barratt's Impulsivity Scale (BIS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), State Food Craving Questionnaire-State (FCQ-S), Trait Food Craving Questionnaire-Trait (FCQ-T), Visual Analogue Scale (VAS), Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
14 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Withdrawn Phase 3 Interventional

Mifepristone in Children With Refractory Cushing's Disease

NCT01925092
View directory record Official record
Conditions
Cushing's Disease
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational

Adolescence, Puberty, and Emotion Regulation

NCT00016731
View directory record Official record
Conditions
Mood Disorder, Neurobehavioral Manifestation, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

NCT03374215
View directory record Official record
Conditions
Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 70 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

NCT05804669
View directory record Official record
Conditions
Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Interventions
atumelnant
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

NCT01374906
View directory record Official record
Conditions
Cushing's Disease
Interventions
pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

NCT02830308
View directory record Official record
Conditions
Endocrine Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 2 Interventional

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900
View directory record Official record
Conditions
Cushing Syndrome
Interventions
LCI699
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting No phase listed Observational

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

NCT04543253
View directory record Official record
Conditions
Cushing Syndrome
Interventions
MUSE biofeedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639
View directory record Official record
Conditions
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 dose
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome

NCT00004343
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational

Diagnostic Performance of Screening Tests for Cushing s Syndrome

NCT00361777
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

NCT06246357
View directory record Official record
Conditions
Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Interventions
[68Ga]Ga-PentixaFor
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting No phase listed Observational

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Osilodrostat
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169
View directory record Official record
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym], Placebo for mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Escondido, California • Gardena, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590
View directory record Official record
Conditions
Hypercortisolism
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Stanford, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

NCT03606408
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
osilodrostat
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 9, 2026, 3:17 AM EDT